Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets-Reference-Cited by-同舟云学术

Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets

Published:2021-10-26 Issue: Volume: Page:
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Munafo Alain¹²,Terranova Nadia¹²,Li Dandan²³,Liu Ping⁴,Venkatakrishnan Karthik²⁵

Affiliation:

1. Merck Institute for PharmacometricsMerck Serono S.A. Lausanne Switzerland

2. An Affiliate of Merck KGaA Darmstadt Germany

3. Merck Serono Pharmaceutical R&D Co. Ltd. China Beijing China

4. Clinical Pharmacology Linking Truth Technology Co., Ltd. Beijing China

5. EMD Serono Research & Development Institute, Inc. Billerica Massachusetts USA

Funder

Merck KGaA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13166

Reference34 articles.

1. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity;Browne P;Neurology,2014

2. Epidemiology of multiple sclerosis in the north‐east (Grampian region) of Scotland–an update;Phadke JG;J Epidemiol Community Health,1987

3. Cladribine: mode of action and implications for treatment of multiple sclerosis;Leist TP;Clin Neuropharmacol,2011

4. The development of cladribine tablets for the treatment of multiple sclerosis: a comprehensive review;Rammohan K;Drugs,2020

5. Both cladribine and alemtuzumab may effect MS via B‐cell depletion;Baker D;Neurol Neuroimmunol Neuroinflamm,2017